Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Withdrawn 4Completed 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Lymphoma 2Recurrence 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Hodgkin Disease 1Colonic Neoplasms 1Caregiver Burden 1Breast Neoplasms 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Health Resources × Clear all
NCT04685551 2022-07-26

Improving Survivorship Among Minority Cancer Dyads

Charles Drew University of Medicine and Science

Phase NA Withdrawn
BreastGastrointestinalThoracic

Caregiver Burden, Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms

NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02701673 2016-05-04

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡